Otonomy Appoints Eric Loumeau as General Counsel and Chief Compliance Officer
May 18 2015 - 7:30AM
Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapeutics for diseases and disorders of the inner and
middle ear, today announced the appointment of Eric Loumeau as
general counsel and chief compliance officer. Mr. Loumeau has over
23 years of experience as in-house legal counsel and compliance
officer for several biopharmaceutical companies and as outside
corporate counsel supporting healthcare and technology-based client
companies.
"Eric is a welcome addition to the Otonomy team given his legal
and senior management experience across a broad range of areas
including public company securities filings, financings,
collaboration agreements, corporate governance, and attention to
general corporate legal matters," said David A. Weber, Ph.D.,
president and CEO of Otonomy. "I expect that Eric will also make a
significant contribution this year in overseeing our corporate
compliance efforts as we prepare for the commercial launch of
AuriProTM in the first quarter of 2016."
Prior to joining Otonomy, Mr. Loumeau was the vice president of
legal affairs at The Medicines Company, which he joined following
the company's acquisition of Rempex Pharmaceuticals. At Rempex, Mr.
Loumeau served as vice president, chief financial officer and chief
compliance officer and in this capacity he was involved in the
completion of several asset acquisitions and financings as well as
having primary responsibility for corporate compliance. Previously,
Mr. Loumeau also served as general counsel and chief compliance
officer for Hollis-Eden Pharmaceuticals, a publicly-traded
biotechnology company. Mr. Loumeau's experience as outside
corporate counsel at national law firms includes roles as a partner
at Bass, Berry & Sims, PLC, and Mintz Levin Cohn Ferris Glovsky
and Popeo PC, partner and associate at Cooley LLP, and an associate
at Skadden, Arps, Slate, Meagher & Flom LLP.
Mr. Loumeau obtained a juris doctorate from Boalt Hall School of
Law at the University of California, Berkeley, including spending
his final year at Harvard Law School through the Harvard-Boalt
Exchange Program. He obtained a bachelor's degree in finance from
Brigham Young University.
About Otonomy
Otonomy is a clinical-stage biopharmaceutical company focused on
the development and commercialization of innovative therapeutics
for diseases and disorders of the ear. Otonomy's proprietary
technology provides sustained exposure of drugs to the middle and
inner ear following a single intratympanic injection. Otonomy has
three product candidates in development. AuriPro™ is an antibiotic
that has completed Phase 3 clinical trials in pediatric patients
with middle ear effusion at the time of tympanostomy tube placement
surgery, and a New Drug Application for AuriPro in this indication
is currently under FDA review. OTO-104 is a steroid that is in the
first of two pivotal clinical studies for the treatment of patients
with Ménière's disease. OTO-311 is an NMDA receptor antagonist in
development as a treatment for tinnitus. For additional information
please visit www.otonomy.com.
CONTACT: Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Vice President
619.849.5377
heidi@canalecomm.com
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jul 2023 to Jul 2024